2-Amino-3-(pyridin-3-yl)-1-propanol | 348619-81-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Amino-3-(pyridin-3-yl)-1-propanol
• 英文别名: 2-Amino-3-(3-pyridyl)-1-propanol；2-Amino-3-(pyridin-3-yl)propan-1-ol；2-amino-3-pyridin-3-ylpropan-1-ol
• CAS: 348619-81-8
• 化学式: C₈H₁₂N₂O
• mdl: MFCD10034609
• 分子量: 152.196
• InChiKey: XKBHUHOUKQVIHT-UHFFFAOYSA-N

物化性质

• 沸点：
  334.4±27.0 °C(Predicted)
• 密度：
  1.139±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  59.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-Amino-3-(pyridin-3-yl)-1-propanol 、 ((S)-2-(((benzyloxy)carbonyl)amino)-3-(4-fluorophenyl)propanoyl)-L-leucine 在 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Exploration of the P1 residue in 3CL protease inhibitors leading to the discovery of a 2-tetrahydrofuran P1 replacement

  摘要：

  DOI：

  10.1016/j.bmc.2024.117618

文献信息

• Fused purine derivatives
  申请人：——

  公开号：US20030176698A1

  公开（公告）日：2003-09-18

  A condensed purine derivative represented by Formula (I): 1 wherein X—Y—Z represents R 1 N—C═O or N═C—W, R 2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted alicyclic heterocyclic group or the like, n represents an integer of from 0 to 3, V 1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, V 2 represents a substituted lower alkyl group or a substituted or unsubstituted aromatic heterocyclic group, and when V 1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and for example, X—Y—Z represents R 1a N—C═O and R 2 represents a substituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted alicyclic heterocyclic group, a halogen atom, a lower alkylthio group, —NR 7 R 8 , —CO 2 H, a lower alkoxycarbonyl group, —COHal, —CONR 9 R 10 or —CHO, V 2 may represent a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group; or a pharmacologically acceptable salt thereof.

  一个由公式(I)表示的浓缩嘌呤衍生物：1 其中，X—Y—Z代表R1N—C═O或N═C—W，R2代表氢原子、取代或未取代的低级烷基团、取代或未取代的芳烷基团、取代或未取代的芳基团、取代或未取代的芳香杂环团、取代或未取代的脂肪杂环团等，n代表从0到3的整数，V1代表氢原子、取代或未取代的低级烷基团、取代或未取代的芳烷基团、取代或未取代的芳基团或取代或未取代的芳香杂环团，V2代表取代的低级烷基团或取代或未取代的芳香杂环团，并且当V1代表氢原子、低级烷基团、取代或未取代的芳烷基团或取代或未取代的芳基团时，例如，X—Y—Z代表R1aN—C═O并且R2代表取代的低级烷基团、取代或未取代的芳烷基团、取代或未取代的脂肪杂环团、卤素原子、低级烷基亚硫酰基团、—NR7R8、—CO2H、低级烷氧羰基团、—COHal、—CONR9R10或—CHO，V2可以代表低级烷基团、取代或未取代的芳烷基团或取代或未取代的芳基团；或其药理可接受的盐。
• [EN] 2,6-DIAMINOPURINE DERIVATIVES<br/>[FR] DERIVES DE LA 2,6-DIAMINOPURINE
  申请人：GLAXO GROUP LIMITED

  公开号：WO1994017090A1

  公开（公告）日：1994-08-04

  (EN) 2,6-Diaminopurine-$g(b)-D-ribofuranuronamide derivatives are described having general formula (I) and salts and solvates thereof, wherein: R1 is hydrogen, C3-8cycloalkyl or C1-6alkyl; R2 is C3-8cycloalkyl, C3-8cycloalkylC1-6alkyl, Alk1Y, -(CHR5)m(Alk2)nZ or appropriately substituted C3-8cycloalkyl, C3-8cycloalkylC1-6alkyl, pyrrolidin-3-yl, 2-oxopyrrolidin-4-yl, 2-oxopyrrolidin-5-yl, piperidin-3-yl or piperidin-4-yl, and Q is oxygen or sulphur. Compounds of formula (I) and their salts and solvates have use in medicine as anti-inflammatory agents, particularly in the treatment of patients with inflammatory conditions who are susceptible to leukocyte-induced tissue damage.(FR) On décrit des dérivés du 2,6-diaminopurine-$g(b)-D-ribofuranuronamide ayant la formule générale (I) ainsi que leurs sels et solvates. Dans cette formule: R1 est un hydrogène, un C3-8cycloalkyle ou un C1-6alkyle; R2 est un C3-8cycloalkyle, un C3-8cycloalkylC1-6alkyle, un Alk1Y, un -(CHR5)m(Alk2)nZ ou un des groupes suivants, portant des substituants appropriés: C3-8cycloalkyle, C3-8cycloalkylC1-6alkyle, pyrrolidin-3-yle, 2-oxopyrrolidin-4-yle, 2-oxopyrrolidin-5-yle, pipéridin-3-yle ou pipéridin-4-yle, et Q est oxygène ou le soufre. Les composés de la formule (I) et leurs sels et solvates sont utiles en médecine comme agents anti-inflammatoires, en particulier pour le traitement de patients souffrant d'affections inflammatoires avec risques de lésions tissulaires, induites par les leucocytes.

  描述了具有通式(I)及其盐和溶剂化物的2,6-二氨基嘌呤-$g(b)-D-核糖尿苷衍生物，其中：R1为氢、C3-8环烷基或C1-6烷基；R2为C3-8环烷基、C3-8环烷基C1-6烷基、Alk1Y、-(CHR5)m(Alk2)nZ或适当取代的C3-8环烷基、C3-8环烷基C1-6烷基、吡咯烷-3-基、2-氧代吡咯烷-4-基、2-氧代吡咯烷-5-基、哌啶-3-基或哌啶-4-基，Q为氧或硫。通式(I)化合物及其盐和溶剂化物在医学上具有抗炎作用，特别是用于治疗易受白细胞诱导的组织损伤的炎症病患。
• FUSED PURINE DERIVATIVES
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1251130A1

  公开（公告）日：2002-10-23

  A condensed purine derivative represented by Formula (I): wherein X--Y--Z represents R1N-C=O or N=C-W, R2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted alicyclic heterocyclic group or the like, n represents an integer of from 0 to 3, V1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, V2 represents a substituted lower alkyl group or a substituted or unsubstituted aromatic heterocyclic group, and when V1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and for example, X--Y--Z represents R1aN-C=O and R2 represents a substituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted alicyclic heterocyclic group, a halogen atom, a lower alkylthio group, -NR7R8, -CO2H, a lower alkoxycarbonyl group, -COHal, -CONR9R10 or -CHO, V2 may represent a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group; or a pharmacologically acceptable salt thereof.

  由式(I)代表的缩合嘌呤衍生物： 其中 X--Y--Z代表 R1N-C=O或N=C-W，R2代表氢原子、取代或未取代的低级烷基、取代或未取代的芳烷基、取代或未取代的芳基、取代或未取代的芳香杂环基团、取代或未取代的脂环杂环基团或类似基团，n代表0至3的整数，V1代表氢原子、V1 代表氢原子、取代或未取代的低级烷基、取代或未取代的芳烷基、取代或未取代的芳基或取代或未取代的芳杂环基团、V2 代表取代的低级烷基或取代的或未取代的芳杂环基团，当 V1 代表氢原子、低级烷基、取代的或未取代的芳烷基或取代的或未取代的芳基时，例如，X--Y--Z 代表 R1aN-C=O，R2 代表取代的低级烷基、取代或未取代的芳烷基、取代或未取代的脂环杂环基、卤素原子、低级烷硫基、-NR7R8、-CO2H、低级烷氧基羰基、-COHal、-CONR9R10 或 -CHO，V2 可代表低级烷基、取代或未取代的芳烷基或取代或未取代的芳基；或其药理学上可接受的盐。
• 2,6-DIAMINOPURINE DERIVATIVES
  申请人：GLAXO GROUP LIMITED

  公开号：EP0680488A1

  公开（公告）日：1995-11-08
• US5889178A
  申请人：——

  公开号：US5889178A

  公开（公告）日：1999-03-30